Dbv technologies to participate in upcoming aaaai/wao joint congress

ChÂtillon, france, february 25, 2025 dbv technologies to participate in upcoming aaaai/wao joint congress dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company, today announced that the company will participate in the american academy of allergy, asthma, and immunology and world allergy organization (aaaai/wao) joint congress, february 28-march 3, 2025, in san diego, ca. an oral abstract presentation by dr. david fleischer, faaaai, facaai, professor of pediatrics at children's hospital colorado, will describe month 60 (m60), end-of-study efficacy and safety results from people (the open-label extension of the 12-month, double-blind placebo-controlled, phase 3 pepites study in peanut allergic children aged 4-11 years).
DBVT Ratings Summary
DBVT Quant Ranking